New York, January 30, 2013 -- Moody's Investors Service commented that Par Pharmaceutical Companies, Inc.'s ("Par") proposed re-pricing of its senior secured term loan has no impact on the company's B2 Corporate Family Rating or stable outlook. Existing debt ratings will also remain unchanged. We note, however, that the proposed amendment is modestly credit positive as it aims to reduce current pricing on the term loan by 50 basis points, as well as reduce the LIBOR floor by 25 basis points. This will result in lower interest expense by about $8 million a year. For more information please go to www.moodys.com for our Issuer Comment.

Vollständigen Artikel bei Moodys lesen